Inter Partes Review Petitions Pile Up
Executive Summary
A list of biopharma IPR petitions by category.
You may also be interested in...
Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent
Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.
New Patent Battleground: Inter Partes Reviews Besiege Innovators
Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.
BioMarin Clears Path For Pompe Treatment After Knocking Out Genzyme Patents
Genzyme’s Myozyme patents invalid for being obvious, Patent Trial and Appeal Board finds in inter partes review.